arrow
D

Douglas A. Rubinson

Dana-Farber Cancer Institute
H指数:37
被引数:7,709

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomized, multiarm, run-in phase trial

吉西他滨和nab-紫杉醇联合或不联合VDR激动剂帕立骨化醇治疗转移性胰腺癌: 一项随机,多臂,磨合期试验

2026-05-250
PRE
Phase 2 Trial Testing The PARP Inhibitor Niraparib In Patients With Advanced Pancreatic Cancer with Pathogenic Variants In BRCA 1, BRCA2, PALB2, ATM and CHEK2
2024-09-150
PRE
An open label, phase II trial of ERK inhibition alone and in combination with autophagy inhibition in patients with metastatic cancreatic cancer
2024-09-150
PRE
Clinical outcomes and ctDNA correlates for CAPOX BETR: a phase II trial of capecitabine, oxaliplatin, bevacizumab, trastuzumab in previously untreated advanced HER2+gastroesophageal adenocarcinoma
2024-08-091
OAAI
Closed-loop automated drug infusion regulator: A clinically translatable, closed-loop drug delivery system for personalized drug dosing

闭环自动药物输注调节器: 用于个性化药物给药的临床可翻译的闭环药物输送系统

MED
IF11.8
2024-07-010
PRE
A phase 1 expansion cohort study evaluating the safety and efficacy of the CHK1 inhibitor LY2880070 with low-dose gemcitabine in metastatic pancreatic adenocarcinoma
2024-01-160
PRE
Long term results and ctDNA correlatives for CAPOX BETR: A multi-center phase II trial of capecitabine, oxaliplatin, bevacizumab and trastuzumab for previously untreated HER2 positive metastatic gastroesophageal adenocarcinoma
2023-04-140
PRE
USP9X mediates an acute adaptive response to MAPK suppression in pancreatic cancer but creates multiple actionable therapeutic vulnerabilities
2023-04-013
OAAI
Spatially Resolved Single-Cell Assessment of Pancreatic Cancer Expression Subtypes Reveals Co-expressor Phenotypes and Extensive Intratumoral Heterogeneity

胰腺癌表达亚型的空间分辨单细胞评估揭示共表达子表型和广泛的肿瘤内异质性

2022-12-0236
OA
Phase II study of pembrolizumab in refractory esophageal cancer with correlates of response and survival
2021-09-3019
OAAI
FGFR2 Extracellular Domain In-Frame Deletions Are Therapeutically Targetable Genomic Alterations That Function as Oncogenic Drivers in Cholangiocarcinoma
2021-04-2961
OA
Leukocyte Heterogeneity in Pancreatic Ductal Adenocarcinoma: Phenotypic and Spatial Features Associated with Clinical Outcome

胰腺导管腺癌的白细胞异质性: 与临床结果相关的表型和空间特征

2021-03-16100
OA
Composition, Spatial Characteristics, and Prognostic Significance of Myeloid Cell Infiltration in Pancreatic Cancer

胰腺癌中髓系细胞浸润的组成,空间特征和预后意义

2021-02-1594
OAAI
Insulin-Like Growth Factor-1 Receptor Expression and Disease Recurrence and Survival in Patients with Resected Pancreatic Ductal Adenocarcinoma
2020-08-0313
OAAI
Effect of High-Dose vs Standard-Dose Vitamin D3 Supplementation on Progression-Free Survival Among Patients With Advanced or Metastatic Colorectal Cancer The SUNSHINE Randomized Clinical Trial
2019-04-09139
OAAI
FOLFOX plus ziv-aflibercept or placebo in first-line metastatic esophagogastric adenocarcinoma: A double-blind, randomized, multicenter phase 2 trial
CANCER
IF5.1
2019-03-2617
OAAI